Abstract 【Objective】To explore the value of positron emission tomography (PET/CT) combined with metabolic parameters in quantitative diagnosis and prediction of lymph node metastasis risk in breast cancer patients. 【Methods】A total of 78 patients with breast cancer admitted to our hospital were enrolled in the study. All patients underwent PET/CT examination and sentinel lymph node (SLN) biopsy before treatment. According to the results of SLN biopsy, 47 patients who showed SLN positive were divided into the metastatic group (n=42) and 6 patients were in the non-metastatic group .The differences of the maximum standard uptake of PET/CT metabolic parameters (SUVmax), tumor metabolic volume (MTV) and total glycolysis (TLG) between the two groups were compared, and the value of PET/CT metabolic parameters in predicting the risk of lymph node metastasis in breast cancer patients was analyzed by ROC. 【Results】SUVmax, MTV and TLG in the metastatic group were significantly higher than those in the non-metastatic group (P<0.05).ROC analysis confirmed that SUVmax, MTV and TLG could all be used to predict the risk of lymph node metastasis in adenocarcinoma patients, and the areas under the curve were 0.901, 0.678 and 0.871, respectively, with P<0.05.The sensitivity, specificity, accuracy, positive predictive value, negative predictive value and Kappa for the combined diagnosis of PET/CT metabolic parameters in predicting the risk of lymph node metastasis in breast cancer patients were 0.857, 0.944, 0.897, 0.897, 0.947 and 0.795 respectively. 【Conclusion】PET/CT metabolic parameters SUVmax≥5.475, MTV≥8.155 cm3, and TLG≥ 22.63 g can be used to predict the risk of lymph node metastasis in breast cancer patients, and furthermore the three parameters combined diagnosis has a higher sensitivity to predict the risk of lymph node metastasis, which is worthy of clinicians' attention.
QIAN Li-xin,QIN Dong-jie. Value of Combined Quantitative Diagnosis of Pet/Ct Metabolic Parameters in Predicting the Risk of Lymph Node Metastasis in Breast Cancer Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(11): 1632-1634.
[1] SANGARAMOORTHY M , KOO J , JOHN E M . Intake of bean fiber, beans, and grains and reduced risk of hormone receptor-negative breast cancer the San Francisco Bay Area Breast Cancer Study[J].Cancer Med,2018, 7(5):2131-2144. [2] POZNAK C V , SOMERFIELD M R , BARLOW W E , et al. Role of bone-modifying agents in metastatic breast cancer: an american society of clinical oncology-cancer care ontario focused guideline update[J].J Clin Oncol,2017, 35(35):3978-3986. [3] 张宗斌, 李佳, 曹卫. 18F-FDG PET/CT在恶性肿瘤神经浸润中的诊断价值[J].癌症进展, 2019, 17(11):1320-1323. [4] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志, 2015, 25(9):692-754. [5] JU W S , CHOI Y S , CHONG S M , et al. Sentinel lymph node identification with radiopharmaceuticals in patients with breast cancer: a comparison of 99mTc-tin colloid and 99mTc-phytate efficiency[J].Breast Cancer Res Treat,2010, 122(2):453-457. [6] ALKAWAA F M.Deep learning accurately predicts estrogen receptor status in breast cancer metabolomics data[J].J Proteome Res,2018, 17(1):337-347. [7] 李艳, 代永亮, 张卫善,等. 18F-FDG PET/CT在乳腺癌诊断和分期中的应用价值[J].实用放射学杂志, 2019, 35(9):1436-1439. [8] 毕伟, 李霞霞, 黄晓红,等. PET/CT MTVwb与临床TNM分期对非小细胞肺癌患者预后的评估价值比较[J].医学影像学杂志, 2020, 30(2):42-46. [9] 黄颖, 程刚. PET/CT在非小细胞肺癌淋巴结转移诊断中的研究进展[J].医学综述, 2020, 26(2):257-262. [10] 高涛涛, 徐美青. 食管鳞癌胃壁内转移患者PET/CT代谢参数与病理特征及预后的关系[J].中国肿瘤生物治疗杂志, 2019, 26(5):530-535. [11] 牛增志. 乳腺癌原发灶18F-FDG PET-CT代谢参数与患者临床病理特征的关系研究[J].中国CT和MRI杂志, 2019, 17(4):83-86.
2021, Vol. 38 
